Inventor · disambiguated record
Yayuan Fu
Also filed as: FU YAYUAN
8 granted patents·20 pending applications·9 citations·filing 2016–2025
78Inventor score
Files withJIANGSU HENGRUI MEDICINE CO11SHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD7HAINAN SIMCERE PHARMACEUTICAL CO LTD3HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD1JIANGSU SIMCERE PHARM CO LTD1
Top patents by PatentIndex Score
28 records- 0187US10543284B2Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereofSUZHOU SUNCADIA BIOPHARMACEUTICALS CO LTD·Filed 2016·Granted Jan 28, 2020·6 cites·36 claims
- 0279US10449250B2Anti-sclerostin antibody, antigen binding fragment and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2016·Granted Oct 22, 2019·2 cites·20 claims
- 0377US12319725B2IL-2 mutant and application thereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2024·Granted Jun 3, 2025·0 cites·16 claims
- 0475US2025382343A1Il-2 Mutants And Uses ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0573US11345753B2TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted May 31, 2022·1 cites·18 claims
- 0672US2024209051A1Il-2 Mutant And Application ThereofHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0769US11981733B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2021·Granted May 14, 2024·0 cites·20 claims
- 0865US12421286B2Il-2 mutant and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2021·Granted Sep 23, 2025·0 cites·14 claims
- 0962US11155617B2LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Granted Oct 26, 2021·0 cites·21 claims
- 1059US2025304717A1Camptothecin derivative and ligand-drug conjugateHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1154US2025270227A1Camptothecin derivative, and pharmaceutical composition and use thereofSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1253US11512129B2TIGIT antibody, antigen-binding fragment thereof, and medical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Granted Nov 29, 2022·0 cites·19 claims
- 1351US2024343803A1Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications ThereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1450US2023138315A1Anti-angptl3 antibody and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2021·Application pending·0 cites
- 1550US2025075006A1Anti-gucy2c nano-antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1650US2024307415A1Steroid compound, and pharmaceutical composition thereof and use thereofJIANGSU SIMCERE PHARM CO LTD·Filed 2022·Application pending·0 cites
- 1750US2025297021A1Bcma antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO NO 1·Filed 2022·Application pending·0 cites
- 1849US2024343811A1Cd16 antibody and use thereofSHANDONG SIMCERE BIOPHARMACUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1949US2025297030A1Anti-muc17 nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2049US2025145705A1Gprc5d antibody and application thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2148US2022220218A1Anti-cd73 antibody, antigen-binding fragment thereof and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2019·Application pending·0 cites
- 2248US2022324953A1Anti-connective tissue growth factor antibody and application thereofJIANGSU HENGRUI MEDICINE CO·Filed 2020·Application pending·0 cites
- 2348US2025136687A1Anti-human cd3 antibody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2446US2025250357A1Anti-msln antibody and application thereofNANJING ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2546US2022031842A1Lag-3 antibody pharmaceutical composition and use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
- 2646US2025026844A1Anti-bcma nanobody and use thereofSHANDONG SIMCERE BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2745US2020347130A1CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use ThereofJIANGSU HENGRUI MEDICINE CO·Filed 2018·Application pending·0 cites
- 2837US2019315886A1Thrombin antibody, antigen-binding fragment and pharmaceutical use thereofJIANGSU HENGRUI MEDICINE CO·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yayuan Fu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →